Papers

2

Total Citations

23

H-Index

2

About

Haruki Kume is a leading urologic oncologist whose research has shaped contemporary treatment paradigms for prostate and bladder cancers in Japan. His work centers on optimizing surgical outcomes and tracking national practice patterns. In a landmark nationwide multi-institutional study (2024, 14 citations), Kume documented a significant shift away from androgen deprivation therapy as first-line treatment for newly diagnosed prostate cancer, reflecting the impact of technological advances on clinical decision-making. He has also been at the forefront of enhancing recovery after surgery (ERAS) protocols, demonstrating in a 2023 study (9 citations) that integrating ERAS with robot-assisted radical cystectomy (RARC) yields superior perioperative outcomes compared to open surgery for muscle-invasive bladder cancer. By systematically comparing open and robotic approaches, Kume provides evidence-based guidance for surgeons adopting minimally invasive techniques. His contributions are vital for clinicians navigating the rapid evolution of urologic oncology, offering data-driven insights that improve patient care and recovery.

Research Focus

Key Achievements

2
H-Index
2
Papers
23
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study
14 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 32
🏛 Institutions: The University of Tokyo, University of Tokyo Hospital

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago